Grzegorz Dzida

Grzegorz Dzida

Auto-generated profile, based on publicly available information

Grzegorz Dzida

Chair and Department of Internal Diseases, Medical University of Lublin, Lublin, Poland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SPSylwia Przybylska-Kuć
Sylwia Przybylska-Kuć
MZMaciej Zakrzewski
Maciej Zakrzewski
ADAndrzej Dybała
Andrzej Dybała
PKPaweł Kiciński
Paweł Kiciński
GDGrzegorz Dzida
Grzegorz Dzida
JMJerzy Mosiewicz
Jerzy Mosiewicz
Amyloid-β 1–40 (Aβ 1–40) and amyloid-β 1–42 (Aβ 1–42) are the proteins known to be involved in the pathogenesis of Alzheimer’s disease (AD)–the most common cause of dementia in the elderly. Hypoxia is suspected to be one of conditions associated with Aβ plasma level increase. A common reason of hypoxia is obstructive sleep apnea (OSA), characterized by recurrent episodes of apnea. The aim of the study was to evaluate plasma Aβ 1–40 and Aβ 1–42 concentrations in patients with OSA. Patients with suspected OSA (n = 112) underwent polygraphic examinations Patients with confirmed OSA (n = 81) showed apnea/hypopnea index greater than or equal to 5. Mild and moderate form of the disease was defined when AHI was 5–30 (n = 38, OSA+), severe–when AHI was >30 (n = 43, OSA++). Individuals with AHI<5 (n = 31) served as control group (OSA-). Aβ 1–40 concentrations in OSA++ (191.1 pg/ml) group was significantly (p<0.05) higher compared with OSA- (76.9 pg/ml) and OSA+ (159.4 pg/ml) and correlated with selected parameters of hypoxemia severity. There were no differences in Aβ 1–42 concentration between the groups. In patients with severe OSA Aβ 1–40 plasma concentrations are significantly higher compared with OSA- and OSA+ and seem to be related to hypoxia severity, which may indicate increased risk of AD development in this group of patients.

26 November 2023 in Archives of Medical Science
Verified
Journal Article
Open access
Maciej BanachMaciej Banach
Maciej Banach
Stanisław SurmaStanisław Surma
Stanisław Surma
Agnieszka Kapłon-CieślickaAgnieszka Kapłon-Cieślicka
Agnieszka Kapłon-Cieślicka
PMPrzemysław Mitkowski
Przemysław Mitkowski
GDGrzegorz Dzida
Grzegorz Dzida
Agnieszka Mastalerz-MigasAgnieszka Mastalerz-Migas
Agnieszka Mastalerz-Migas
Lipid disorders, primarily hypercholesterolemia, are the most common cardiovascular (CV) risk factor in Poland (this applies even 3/4 of people). The low-density lipoprotein cholesterol (LDL-C) serum level is the basic lipid parameter that should be measured to determine CV risk and determines the aim and target of lipid-lowering treatment (LLT). Lipid-lowering treatment improves cardiovascular prognosis and prolongs life in both primary and secondary cardiovascular prevention. Despite the availability of effective lipid-lowering drugs and solid data on their beneficial effects, the level of LDL-C control is highly insufficient. This is related, among other things, to physician inertia and patients’ fear of side effects. The development of lipidology has made drugs available with a good safety profile and enabling personalisation of therapy. Pitavastatin, the third most potent lipid-lowering statin, is characterised by a lower risk of muscle complications and new cases of diabetes due to its being metabolised differently. Thus, pitavastatin is a very good therapeutic option in patients at high risk of diabetes or with existing diabetes, and in patients at cardiovascular risk. This expert opinion paper attempts at recommendation on the place and possibility of using pitavastatin in the treatment of lipid disorders.

1 February 2013 in Drugs & Aging
Verified
Journal Article
Open access
PDF file
EKEddy Karnieli
Eddy Karnieli
FBFlorian M. M. Baeres
Florian M. M. Baeres
GDGrzegorz Dzida
Grzegorz Dzida
QJQiuhe Ji
Qiuhe Ji
RLRobert Ligthelm
Robert Ligthelm
JYJean-François Yale
Jean-François Yale
Objectives Older patients are particularly vulnerable to hypoglycaemia. The aim of this study was to evaluate the response to initiation of once-daily insulin detemir in patients aged ≥75 years with type 2 diabetes mellitus (T2DM) treated with one or more oral antidiabetic drugs (OADs). Methods A sub-analysis was conducted using data from SOLVE (Study of Once daily LeVEmir), a 24-week observational study involving 3,219 investigators and 2,817 project sites from ten countries. Routine clinical practice was followed; there were no study-prescribed procedures. The total cohort comprised 17,374 participants, of whom 2,398 (14 %) were aged ≥75 years. The physicians collected information from patient recall, the patients’ medical records and their self-monitored blood glucose diaries (if kept). Results Pre-insulin glycated haemoglobin (HbA1c) was similar between participants aged ≥75 years and those aged <75 years (HbA1c 8.8 ± 1.5 % vs. 8.9 ± 1.6 % [mean ± SD], respectively). After 24 weeks of treatment, similar reductions in HbA1c were observed in the two subgroups: 7.6 ± 1.1 % and 7.5 ± 1.2 % in participants aged ≥75 years and those aged <75 years, respectively. The incidence of severe hypoglycaemia (episodes per patient-year) decreased during the study in both age groups (from 0.057 to 0.007 in patients aged ≥75 years; from 0.042 to 0.005 in patients aged <75 years), while minor hypoglycaemia increased from 1.1 to 2.0 and from 1.7 to 1.8 episodes per patient-year in the older and younger age groups, respectively. Average weight reduction was similar in both groups: −0.5 kg (≥75 years) and −0.6 kg (<75 years). Conclusion In both the older and younger age groups, the addition of once-daily insulin detemir to existing OAD regimens was effective and safe. In older patients, an improvement in HbA1c of 1.2 % was not associated with an increased risk of severe hypoglycaemia or weight gain.

13 December 2024 in Archives of Medical Science
Verified
Journal Article
Open access
Maciej BanachMaciej Banach
Maciej Banach
Stanisław SurmaStanisław Surma
Stanisław Surma
GDGrzegorz Dzida
Grzegorz Dzida
JJJacek Jozwiak
Jacek Jozwiak
BOBogusław Okopień
Bogusław Okopień
Andrzej GrzybowskiAndrzej Grzybowski
Andrzej Grzybowski
CVD prevention does not only mean effective fight against the existing cardiovascular risk factors, but also against their complications, including micro- and macrovascular ones. In relation to obesity, prediabetes and diabetes, we recognize a number of potential dangerous non-cardiovascular complications, such as neuropathy, nephropathy and retinopathy. The latter’s prevalence is even 30-40% and may appear in as many as 15% of patients with prediabetes. Not treated well might result in necessity of eye surgery or even vision loss. Fenofibrate has had a long history of evidence suggesting preventive role in primary and especially secondary prevention of retinopathy, what has been being investigated since the FIELD trial 19 years ago. In this Position Paper we have reviewed the current stage of knowledge on possible mechanisms, by which fenofibrate may contribute to retinopathy prevention, available data on safety and efficacy, to finally recommend administrating fenofibrate in prevention of this dangerous diabetic complication.

1 October 2015 in Primary Care Diabetes
Verified
Journal Article
Open access
GDGrzegorz Dzida
Grzegorz Dzida
EKEddy Karnieli
Eddy Karnieli
ASAnne Louise Svendsen
Anne Louise Svendsen
KSKristine Steensen Sølje
Kristine Steensen Sølje
NHNorbert Hermanns
Norbert Hermanns
To study the frequency and intensity of depressive symptoms and associations with physician resource utilisation following insulin initiation in patients with type 2 diabetes mellitus. SOLVE was a 24-week observational study. In this sub-analysis of data from Poland, depressive symptoms were evaluated using the Patient Health Questionnaire (PHQ)-9. PHQ-9 was completed by 942 of 1169 patients (80.6%) at baseline, and 751 (64.2%) at both baseline and final (24-week) visit. PHQ-9 scores indicated depressive symptoms in 45.6% (n=430) at baseline, and 27.2% (n=223) at final visit. Mean PHQ-9 change was -2.38 [95% CI -2.73, -2.02], p<0.001. Depressive symptoms at baseline (OR 6.32, p<0.001), microvascular disease (OR 2.45, p=0.016), number of physician contacts (OR 1.16, p=0.009), and change in HbA1c (OR 0.60, p=0.025) were independently associated with moderate/severe depressive symptoms at final visit. Patients with more severe depressive symptoms spent more time training to self-inject (p=0.0016), self-adjust (p=0.0023) and manage other aspects of insulin delivery (p<0.0001). Patients with persistent depressive symptoms had more telephone contacts and dose changes at final visit than those without (both p<0.05). Depressive symptoms are common with type 2 diabetes and associated with increased healthcare utilisation, reinforcing the need for holistic interdisciplinary management approaches.

22 December 2020 in Annals of Agricultural and Environmental Medicine
Verified
Journal Article
Open access
APAndrzej Prystupa
Andrzej Prystupa
PKPaweł Kiciński
Paweł Kiciński
DLDorota Luchowska-Kocot
Dorota Luchowska-Kocot
Grzegorz Józef NowickiGrzegorz Józef Nowicki
Grzegorz Józef Nowicki
GDGrzegorz Dzida
Grzegorz Dzida
LPLech Panasiuk
Lech Panasiuk
Introduction. Alcohol consumption causes acute and chronic liver injury. The clinical forms of alcohol liver disease (ALD) include steatosis, hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) associated with liver cirrhosis. Objective. The aim of the study was to determine the levels of novel markers of fibrogenesis and angiogenesis in patients with alcoholic liver cirrhosis. Serum levels of angiopoietin-like peptide 4 (ANGPTL-4), asialoglycoprotein receptor 1 (ASGP-R1), and S100 calcium-binding protein A8 (S100A8) were assessed. Levels of hyaluronic acid (Hyal) and collagen IV (Coll IV) werealso determined at various stages of alcoholic liver cirrhosis. Materials and method. The study group consisted of 72 patients with alcoholic liver cirrhosis, while the control group included 22 healthy subjects without a history of alcohol abuse. The degree of liver cirrhosis was evaluated according to the Pugh-Child criteria (Pugh-Child score). Based on thse scores, patients were assigned to one of three groups: Pugh-Child (P-Ch) A - 21 with stage A, P-Ch B - 23 with stage B and P-Ch C - 28 with stage C liver cirrhosis. Serum levels of markers were determined using ELISA. Results. The study findings demonstrated higher levels of ANGPTL-4, ASGP-R1, S100A, hyaluronic acid and serum collagen IV in the group of patients with alcoholic liver cirrhosis, compared to the control group. Furthermore, their levels increased with the progression of alcoholic liver cirrhosis. Conclusions. The biomarkers analysed in the study may be useful for diagnosis and prognosis in patients with alcoholic liver cirrhosis.